Abstract
The unrecognized importance, danger and costs of hepatitis in the 21st century
cannot be understated or underestimated. While we were fortunate that, in the
latter part of the 20th century, in that hepatitis was fairly well held in
check, the impact of the disease on world society is still highly significant
and now presenting a major crisis in public health circles.
In his exhaustive analysis of the potential diagnosis, screening and
therapeutic markets for hepatitis, Ken Krul, PhD. advises companies to think
on a global basis. In this study, Global Hepatitis Strategies Krul
examines the potential market, epidemiology (hepatitis patient trends) and
technology to provide a clear understanding of the opportunities and
challenges awaiting companies competing in this market.
As part of the market analysis this report includes
- Extensive Statistics of Incidence and Prevalence of Hepatitis
Across the 6 Major WHO Regions (Americas, Europe, Africa, Western Pacific,
Southeast Asia, Eastern Mediterranean)
- Etiology, Prophylaxis, and Therapy for Hepatitis A, B, C, D and E.
- Theoretical Revenues for Diagnosis, Screening and Therapeutics
representing the potential marketplace if all screening options are pursued.
- Realistic Market Revenues representing the likely marketplace.
- Global Distribution of Therapeutics and Diagnostics Revenues across
Major 6 WHO regions
- Over 40 Figures and Tables making information accessible.
Product managers, Marketing executives at pharmaceutical and diagnostic
companies; as well as investment professionals are among those who will find
this survey a critical resource.
View Cart
